Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Trading Down 1.3 %

NASDAQ EVGN opened at $1.55 on Wednesday. The firm has a market capitalization of $8.32 million, a P/E ratio of -0.35 and a beta of 1.30. The firm’s fifty day moving average price is $1.59 and its two-hundred day moving average price is $2.67. Evogene has a 1 year low of $1.20 and a 1 year high of $10.40.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.